All In Biotech

Drug Trial Radar · NCT05421858

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Dec 11, 2024

Primary completion

Jan 30, 2028

Study completion Jan 30, 2028

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Jun 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosmanogepix tablets. One-third of all patients will receive a standard of care regimen of caspofungin Intravenous (IV) infusion followed by optional fluconazole capsules. Fosmanogepix or caspofungin will first be given as an Intravenous (IV) infusion directly into a vein in the arm each day at the study clinic. Fosmanogepix tablets or fluconazole capsules will be taken orally by mouth daily either at the study clinic, or at home if patients are well enough to be discharged from the hospital. The treatment effect in patients receiving fosmanogepix to those receiving caspofungin/ fluconazole will be compared. The primary aim is to show that fosmanogepix is not inferior (not worse) to caspofungin/ fluconazole with a noninferiority margin of 15%. The duration of study treatment and number of study visits will vary depending on how long the patient will be treated for the infection. Treatment will continue for a maximum of 6 weeks depending on when the infection is cleared and whether other symptoms related to the infection have improved. There will also be a follow-up visit 6 weeks after the study treatment was stopped.

Conditions

  • Candidemia
  • Candidiasis, Invasive

Interventions

  • FosmanogepixDrug

    IV infusion

  • FosmanogepixDrug

    Oral tablet

  • CaspofunginDrug

    IV infusion

  • FluconazoleDrug

    Fluconazole oral capsule

  • PlaceboDrug

    Matching placebo for caspofungin (IV infusion)

  • PlaceboDrug

    Matching placebo for fluconazole (oral capsule)

  • PlaceboDrug

    Matching placebo for fosmanogepix (IV infusion)

  • PlaceboDrug

    Matching placebo for fosmanogepix (oral tablet)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients alive at Day 30Time frame: Day 30
  2. Proportion of patients with an overall response of treatment success at end of study treatment (EOST)Time frame: EOST (up to Day 42)

Locations

146 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham School of Medicine, Department of Medicine

    Birmingham, Alabama · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • David Geffen School of Medicine at UCLA

    Los Angeles, California · Recruiting

  • UC Davis Medical Center

    Sacramento, California · Recruiting

  • Emory University Hospital - Clifton Road

    Atlanta, Georgia · Recruiting

  • Augusta University Medical Center

    Augusta, Georgia · Recruiting

  • Indiana University Methodist Hospital

    Indianapolis, Indiana · Recruiting

  • University of Kentucky College of Medicine

    Lexington, Kentucky · Withdrawn

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • University of Michigan Health System (UMHS) - A. Alfred Taubman Health Care Center

    Ann Arbor, Michigan · Recruiting

  • DMC Harper University Hospital

    Detroit, Michigan · Recruiting

  • Henry Ford Hospital, Department of Medicine, Division of Infectious Diseases

    Detroit, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Washington University School of Medicine, Infectious Diseases Clinical Research Unit

    St Louis, Missouri · Recruiting

  • Weill Cornell Medical College - NewYork-Presbyterian Hospital

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • University of Pennsylvania School of Medicine

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Presbyterian

    Pittsburgh, Pennsylvania · Recruiting

  • Houston Methodist Hospital - Texas Medical Center

    Houston, Texas · Recruiting

  • The University of Texas Health Science Center at Houston

    Houston, Texas · Recruiting

  • U.T. MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas · Recruiting

  • Carilion Clinic

    Roanoke, Virginia · Recruiting

  • Central Hospital de San Isidro Melchor Posse

    Buenos Aires, Argentina · Recruiting

  • Buenos Aires Italian Hospital, Department of Infectious Diseases

    Buenos Aires, Argentina · Recruiting

  • Cordoba Private University Hospital, Department of Infectious Diseases

    Córdoba, Argentina · Recruiting

  • Italian Hospital of La Plata, Department of Infectious Diseases

    La Plata, Argentina · Recruiting

  • Central Hospital Mendoza

    Mendoza, Argentina · Terminated

  • British Sanatorium SA

    Rosario, Argentina · Recruiting

  • Monash Medical Center Clayton

    Clayton, Australia · Recruiting

  • Westmead Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Peter MacCallum Cancer Center, State

    Melbourne, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Recruiting

  • University Hospital Graz, Department of Internal Medicine

    Graz, Austria · Recruiting

  • Kepler University Hospital GmbH, Department of Pulmonology, Clinical Department of Infectious Diseases

    Linz, Austria · Recruiting

  • Medical University Vienna

    Vienna, Austria · Recruiting

  • Hospital Favoriten, Department of Internal Medicine IV - Infectious Diseases and Tropical Medicine

    Vienna, Austria · Recruiting

  • General Hospital Saint-Jan

    Bruges, Belgium · Recruiting

Showing 40 of 146 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.